• Mashup Score: 0

    Revitalizing the cancer therapeutics industry – 90% of clinical trials fail, with the average trial costing $793M. Despite its $100K/year price, immunotherapy is only partially effective in 17% of patients.

    Tweet Tweets with this article
    • Neural network analysis of germline+tumor molecular alterations shows large impact of host to predict 5-yr survival with high accuracy post-#radicalcystectomy for muscle-invasive #bladdercancer @LayneSadler https://t.co/meEm1f6TxI https://t.co/6VnqZ9fTCz @onclive